E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
muscle-invasive urothelial bladder cancer |
|
E.1.1.1 | Medical condition in easily understood language |
muscle-invasive urothelial bladder cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess whether pembrolizumab (MK-3475) results in pathological complete response rates (herein referred to as either “pT0” or “pCR”) in T2-T3a N0M0 UC of the bladder. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate radiological response on those patients with measurable disease (at baseline). Response (CR and PR) after 3 cycles of treatment with the study drug. Safety of MK-3475. To evaluate the pathological responses in patients with upper tract UC provided as a separate cohort |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
This part of the study consists of a series of tests on blood and tumor tissue, including the determination of circulating biomarkers, which may be related to the response to immunotherapeutics such as pembrolizumab. |
|
E.3 | Principal inclusion criteria |
1. Willing and able to provide written informed consent. 2. Ability to comply with the protocol. 3. Age ≥ 18 years. 4. Histopathologically confirmed transitional cell carcinoma. Patients with mixed histologies are required to have a dominant (i.e. 50% at least) transitional cell pattern. 5. Fit and planned for cystectomy (according to local guidelines). 6. Clinical stage T2-T3b N0 M0 disease by CT (or MRI) + PET/CT (within 4 weeks of randomization by RECIST v1.1). 7. Residual disease after TURB (surgical opinion, cystoscopy or radiological presence). 8. Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens (blocks preferred) or at least 15 unstained slides, with an associated pathology report, for testing at the study sponsor site and determined to be evaluable for tumor PD-L1 expression prior to study enrolment; patients with fewer than 15 unstained slides available at baseline (but no fewer than 10) may be eligible following discussion with Merck representatives. 9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 10. Adequate hematologic and end-organ function defined by the following laboratory results obtained within 28 days prior to the first study treatment: 11. Absolute Neutrophil Count ≥ 1,500 cells/μL (without granulocyte colony-stimulating factor support within 2 weeks prior to Cycle 1, Day 1). 12. Lymphocyte count ≥ 500/μL. 13. Platelet count ≥ 100,000/μL (without transfusion within 2 weeks prior to Cycle 1, Day 1). 14. Haemoglobin ≥ 9.0 g/dL - Patients may be transfused or receive erythropoietic treatment to meet this criterion. 15. AST, ALT, and alkaline phosphatase ≤ 2.5 times the upper limit of normal (ULN), with the following exceptions: a. Patients with known Gilbert disease who have serum bilirubin level ≤ 3 × ULN may be enrolled. 16. INR and aPTT ≤ 1.5 × ULN. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose. 17. Calculated creatinine clearance ≥ 30 mL/min (Cockcroft-Gault formula). |
|
E.4 | Principal exclusion criteria |
Patients taking regular oral steroids, above the allowed limit of 10mg/day methylprednisolone or analogues, for any reason. Patients must not have had steroids for 28 days prior to study entry. Previously intravenous chemotherapy bladder cancer. Patients who have previously had radiotherapy or concurrent chemo-radiation would be eligible. Malignancies other than UBC within 5 years prior to Cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically with curative intent) or localized prostate cancer treated with curative intent and absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer (Gleason score ≤ 3 + 4 and PSA < 10 ng/mL undergoing active surveillance and treatment naive). Evidence of measurable nodal or metastatic disease. Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome). Pregnant female patients. All female patients of childbearing potential with a positive pregnancy test within 2 weeks prior to the first dose of study treatment will be excluded from the study. A WOCBP should agree to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to enrolment, unstable arrhythmias, or unstable angina. Has a history or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful. Screening corrected QT interval (QTc) interval >480 msec is excluded (corrected by Fridericia formula or Bazett formula). In the event that a single QTc is >480 milliseconds, the participant may enroll if the average QTc for the 3 ECGs is <480 milliseconds. Severe infections within 4 weeks prior to enrolment in the study including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia. Major surgical procedure within 4 weeks prior to enrolment or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis. Received therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to randomization (Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible). History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the pembrolizumab formulation History of autoimmune disease including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosis, Sjögren’s syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. Patients with a history of autoimmune-related hypothyroidism, unless on a stable dose of thyroid-replacement hormone. Patients with uncontrolled Type 1 diabetes mellitus Patients with prior allogeneic stem cell or solid organ transplantation. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan (History of radiation pneumonitis in the radiation field (fibrosis) is permitted). Positive test for HIV. Patients with active hepatitis infection (defined as having a positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C. Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc] antibody test) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA. Patients with active tuberculosis. Prior treatment with anti-CTLA4, CD137 agonists, anti−programmed death−1 (PD-1), or anti−PD-L1 therapeutic antibody or pathway-targeting agents. Administration of a live, attenuated vaccine within 4 weeks prior to enrolment or anticipation that such a live, attenuated vaccine will be required during the study |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Pathologic complete response (pCR) is the primary endpoint. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints will include downstaging to non-muscle invasive disease, PFS, OS, radiological response on those patients with measurable disease (at baseline, response [CR and PR] by RECIST v1.1), and toxicity. All toxicities will be evaluated and recorded based on the NCI common toxicity criteria (CTCAE v4.03) described by frequency and grade, by cycle and over all cycles, with the maximum grade over all cycles used as the summary measure per patient. Clavien-Dindo assessment will be utilized for grading the surgical complications (Grades I to IV). PFS time will be calculated as the interval between the date of enrollment and that of first disease progression or death regardless of the cause, with censoring at the date of last follow-up visit for patients alive and without progression. OS will be calculated from the date of enrollment to that of death/last follow-up. The PFS and OS curves will be estimated by means of the Kaplan-Meier method. Additional (translational) goals of this study are twofold, firstly to help refine the molecule’s development plan aiding prioritization of selected indications. Secondly to identify potential biomarkers that could be used for correlation with response and outcome in this setting of bladder cancer patients as well as more advanced settings in this indication |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 2 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 5 |